Commercial-stage biotechnology company Adaptive Biotechnologies Corporation (Nasdaq:ADPT) and oncology testing services provider NeoGenomics Inc (Nasdaq:NEO) on Tuesday announced a strategic collaboration to expand access to minimal residual disease (MRD) monitoring for patients with certain blood cancers.

This partnership integrates Adaptive's clonoSEQ MRD test with NeoGenomics' COMPASS and CHART assessment services.

clonoSEQ, an FDA-cleared in vitro diagnostic (IVD) test, detects MRD in lymphoid cancers. COMPASS and CHART offer comprehensive and personalised assessment services for complex blood cancers.

The collaboration will enable clinicians to provide patients with personalised treatment strategies based on advanced MRD monitoring and real-time insights into disease progression.

Initially, the partnership will focus on patients with multiple myeloma, B-cell acute lymphoblastic leukaemia, chronic lymphocytic leukaemia and diffuse large B-cell lymphoma.

clonoSEQ testing will continue to be performed by Adaptive Biotechnologies' CLIA-certified laboratory.

The companies expect to launch cross-promotional efforts later this year.